Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Forum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Reviewers
    • Subscribers
    • Advertisers
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Reprints and Permissions
    • Accessibility
  • Contact Us
  • Meetings
  • JRheum Supplements
  • Publisher Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Publisher Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Forum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Reviewers
    • Subscribers
    • Advertisers
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Reprints and Permissions
    • Accessibility
  • Contact Us
  • Meetings
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
EditorialEditorial

Posterior Reversible Encephalopathy Syndrome: Increasing Recognition of an Important Clinical Entity in Young Patients with Systemic Lupus Erythematosus

TANIA CELLUCCI and SUSANNE M. BENSELER
The Journal of Rheumatology August 2011, 38 (8) 1544-1545; DOI: https://doi.org/10.3899/jrheum.110774
TANIA CELLUCCI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUSANNE M. BENSELER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Systemic lupus erythematosus (SLE) is a chronic relapsing, remitting, multisystem disease1. Twenty percent of patients present at a younger age, with an onset of symptoms prior to age 18 years. Neuropsychiatric involvement is reported in a quarter of young lupus patients, of which 40% initially present with neuropsychiatric symptoms and 70% have their first manifestation within a year of diagnosis2. The diagnosis of neuropsychiatric lupus in children and young adults is based on the 1999 American College of Rheumatology nomenclature and case definitions3,4. Headaches, cognitive dysfunction, cerebrovascular disease, and seizures are among the most common clinical phenotypes in the spectrum of neuropsychiatric lupus2. Cerebrovascular disease includes cerebral vein thrombosis, microthrombotic vasculopathy, and inflammatory vasculitis, predominantly of the small vessels. Frequently, cerebrovascular disease and proliferative nephritis are concomitantly present in young lupus patients5. Headaches, seizures, and cerebrovascular disease were found to cluster, suggesting a common underlying vascular pathology2. Brain biopsies are rarely done. However, case reports demonstrated histological evidence of immune complex-mediated vasculitis6.

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity of headaches, encephalopathy, and seizures associated with magnetic resonance imaging (MRI) findings of reversible vasogenic subcortical edema without infarction7. PRES was first reported in patients with hypertension and was thought to be purely a hypertensive encephalopathy. In 1996, Hinchey, et al first described the link of immunosuppressive medication, renal disease, hypertension, and PRES8. Subsequently, risk factors associated with development of PRES in lupus patients were identified including vascular disease with endothelial damage, disrupted blood-brain barrier, hypertension, systemic inflammation, and cytotoxic treatment regimens9,10.

In 2010, Muscal, et al determined the characteristic MRI findings in young lupus patients with PRES11. They reported diffuse bilateral gray and white-matter findings in the majority, while only half the patients had the classical posterior fossa lesions. The authors identified reversible diffusion changes in all patients, providing guidance for neuroimaging evaluation of young lupus patients with suspected PRES11.

The case series by Varaprasad, et al in this issue of The Journal adds to our understanding of the clinical spectrum of PRES12. The authors discuss the clinical and laboratory features, treatment, and outcomes of a group of 13 adolescents and young adults with SLE and PRES. In this study, the median disease duration prior to the onset of PRES was 6 months, which is significantly shorter than the mean disease duration of 61.8 months previously reported by Baizabal-Carvallo, et al9. This finding highlights the fact that PRES may develop early in the course of SLE, when disease activity is high. Active lupus nephritis was also identified in 10 of 13 patients, which is in keeping with previous studies that demonstrate an association between PRES and lupus nephritis9,11,13. Previous studies also documented renal insufficiency in over 75% of patients with SLE and PRES9,14. However, this new case series and another recent report of PRES in young lupus patients have shown a lower frequency of concurrent renal failure11,12. This suggests that disease activity, rather than fluid overload secondary to renal insufficiency, is a critical factor in the pathogenesis of PRES.

Common presenting features of PRES include headaches, seizures, decreased level of consciousness, temporary vision loss, and paresis9,12,13,14. PRES is typically associated with the sudden onset of severe hypertension14,15. However, Varaprasad, et al clearly demonstrate that patients with PRES may have blood pressure at near-normal, which broadens the clinical spectrum of this condition12. Previous reports have attributed the occurrence of PRES in normotensive patients to medications, such as corticosteroids, cyclophosphamide, and cyclosporine8,16,17. However, this study also identified PRES in treatment-naive patients with mild hypertension12. Further, several patients treated with cyclophosphamide were able to continue this medication without the recurrence of PRES after the acute episode had been treated12. These findings emphasize the complexity of the underlying pathogenic mechanisms leading to PRES.

The differential diagnosis for a patient with lupus who develops headache, hypertension, and seizures includes cerebrovascular disease, neuropsychiatric lupus and PRES. Since PRES may develop in the context of mild hypertension or normotension, blood pressure alone cannot differentiate these entities. All 3 may occur early in disease and in the presence or absence of immunosuppressive medications. However, neuroimaging may be more helpful in distinguishing among these conditions. Characteristic MRI findings in PRES include diffuse bilateral changes involving gray and white matter with altered diffusion11. In contrast, MRI lesions in neuropsychiatric lupus are typically small and multifocal, and predominantly involve the white matter2. Cerebrospinal fluid analysis may be normal in any of these conditions, although it is more likely to be normal in PRES12. Neurological recovery generally occurs more rapidly (within 7 to 10 days) following treatment in PRES compared to neuropsychiatric lupus.

The pathogenesis of PRES in lupus is multifactorial. The underlying susceptibility of the cerebrovascular system in addition to insults, such as inflammation secondary to active lupus, hypertension, nephritis, and cytotoxic medications, can lead to the development of the condition we recognize as PRES. The study by Varaprasad, et al in this issue widens the range of signs and symptoms that may be associated with PRES and broadens our understanding of the context in which PRES develops.

REFERENCES

  1. 1.↵
    1. Kamphuis S,
    2. Silverman ED
    . Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538–46.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Benseler SM,
    2. Silverman ED
    . Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007;16:564–71.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Singh S,
    2. Gupta MK,
    3. Ahluwalia J,
    4. Singh P,
    5. Malhi P
    . Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. Rheumatol Int 2009;29:1455–61.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Muscal E,
    2. Bloom DR,
    3. Hunter JV,
    4. Myones BL
    . Neurocognitive deficits and neuroimaging abnormalities are prevalent in children with lupus: clinical and research experiences at a US pediatric institution. Lupus 2010;19:268–79.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Hiraki LT,
    2. Benseler SM,
    3. Tyrrell PN,
    4. Hebert D,
    5. Harvey E,
    6. Silverman ED
    . Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008;152:550–6.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Rizos T,
    2. Siegelin M,
    3. Hahnel S,
    4. Storch-Hagenlocher B,
    5. Hug A
    . Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus 2009;18:361–3.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Lee VH,
    2. Wijdicks EF,
    3. Manno EM,
    4. Rabinstein AA
    . Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65:205–10.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Hinchey J,
    2. Chaves C,
    3. Appignani B,
    4. Breen J,
    5. Pao L,
    6. Wang A,
    7. et al.
    A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Baizabal-Carvallo JF,
    2. Barragan-Campos HM,
    3. Padilla-Aranda HJ,
    4. Alonso-Juarez M,
    5. Estanol B,
    6. Cantu-Brito C,
    7. et al.
    Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg 2009;111:359–63.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Punaro M,
    2. Abou-Jaoude P,
    3. Cimaz R,
    4. Ranchin B
    . Unusual neurologic manifestations (II): posterior reversible encephalopathy syndrome (PRES) in the context of juvenile systemic lupus erythematosus. Lupus 2007;16:576–9.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Muscal E,
    2. Traipe E,
    3. de Guzman MM,
    4. Myones BL,
    5. Brey RL,
    6. Hunter JV
    . MR imaging findings suggestive of posterior reversible encephalopathy syndrome in adolescents with systemic lupus erythematosus. Pediatr Radiol 2010;40:1241–5.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Varaprasad IR,
    2. Agrawal S,
    3. Prabu VN,
    4. Rajasekhar L,
    5. Kanikannan MA,
    6. Narsimulu G
    . Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Rheumatol 2011;38:1607–11.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Kur JK,
    2. Esdaile JM
    . Posterior reversible encephalopathy syndrome — an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol 2006;33:2178–83.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Leroux G,
    2. Sellam J,
    3. Costedoat-Chalumeau N,
    4. Le Thi Huong D,
    5. Combes A,
    6. Tieulie N,
    7. et al.
    Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature. Lupus 2008;17:139–47.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Ni J,
    2. Zhou LX,
    3. Hao HL,
    4. Liu Q,
    5. Yao M,
    6. Li ML,
    7. et al.
    The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging 2010 June 21. [Epub ahead of print]
  16. 16.↵
    1. Magnano MD,
    2. Bush TM,
    3. Herrera I,
    4. Altman RD
    . Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2006;35:396–402.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bartynski WS
    . Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 2008;29:1043–9.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology: 38 (8)
The Journal of Rheumatology
Vol. 38, Issue 8
1 Aug 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Posterior Reversible Encephalopathy Syndrome: Increasing Recognition of an Important Clinical Entity in Young Patients with Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Citation Tools
Posterior Reversible Encephalopathy Syndrome: Increasing Recognition of an Important Clinical Entity in Young Patients with Systemic Lupus Erythematosus
TANIA CELLUCCI, SUSANNE M. BENSELER
The Journal of Rheumatology Aug 2011, 38 (8) 1544-1545; DOI: 10.3899/jrheum.110774

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Posterior Reversible Encephalopathy Syndrome: Increasing Recognition of an Important Clinical Entity in Young Patients with Systemic Lupus Erythematosus
TANIA CELLUCCI, SUSANNE M. BENSELER
The Journal of Rheumatology Aug 2011, 38 (8) 1544-1545; DOI: 10.3899/jrheum.110774
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Mirror, Mirror, on the Wall, Which Is the Most Effective Biologic of All?
  • Toward a Multibiomarker Panel to Optimize Outcome and Predict Response in Juvenile Idiopathic Arthritis
  • A Changing Landscape of Gout: Comorbidity Matters
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Forum

Info For

  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Subscribers
  • Advertisers

About Us

  • About Us
  • Editorial Board
  • Letter from the Editor
  • Duncan A. Gordon Award
  • Reprints and Permissions
  • Accessibility

More

  • Contact Us
  • Feedback
  • My Alerts
  • My Folders
  • Meetings
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Company Limited
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire